Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Engineered Immune Effector cells
- Development stage
- Phase 2
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Engineered Immune Effector (EIE) cells are an autologous cell therapy platform developed by the Shenzhen Geno-Immune Medical Institute (GIMI) for the treatment of various advanced cancers. The therapy involves the genetic modification of a patient's own immune effector cells to express receptors that specifically target tumor-associated antigens (TAAs). Once re-infused into the patient, these engineered cells recognize and eliminate cancer cells expressing the target antigens. The EIE platform is part of GIMI's broader immunotherapy portfolio, which includes CAR-T and dendritic cell vaccines, and is designed to address both hematological malignancies and solid tumors. It is currently being evaluated in Phase 1/2 clinical trials to assess safety and therapeutic efficacy in patients with refractory or advanced disease.
- Other names
- Tumor Associated Antigen-specific Engineered Immune Effector CellsEngineered Immune CellsEIE therapy
Beyond the preview
Go deeper on Engineered Immune Effector cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engineered Immune Effector cells.